Multinational phase 3 trial of sacituzumab govitecan for HR-positive and HER2-negative metastatic breast cancer
Prof. Hope Rugo
The multinational phase 3 TROPiCS-02 trial, at 91 centers across nine countries, randomized patients with pretreated, endocrine-resistant, HR-positive and HER2-negative metastatic breast cancer to the Trop-2 directed antibody-drug conjgate sacituzumab govitecan (SG) or physician’s choice of chemotherapy. The median overall survival was longer with SG than with chemotherapy, which was seen in almost all subgroups. SG compared with chemotherapy resulted in higher ORR and better QOL. The safety profile of SG was consistent with earlier reports. The authors conclude that these data support SG as a new treatment option for this patient population.
